MDWD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration...

Stats
Today's Volume	47 605.00
Average Volume	72 250.00
Market Cap	166.96M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.400 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-23.45
ATR14	$0.0850 (0.49%)

Volume Correlation

Long: 0.13 (neutral)

Short: -0.73 (moderate negative)

Signal:(49.378) Neutral

Mediwound Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mediwound Ltd Correlation - Currency/Commodity

0.52
( weak )

0.75
( moderate )

-0.53
( weak negative )

0.83
( strong )

0.81
( strong )

0.79
( moderate )

Mediwound Ltd Financials

Annual	2023
Revenue:	$18.69M
Gross Profit:	$2.95M (15.77 %)
EPS:	$-0.750

Q4	2023
Revenue:	$5.34M
Gross Profit:	$719 000 (13.47 %)
EPS:	$-0.190

Q3	2023
Revenue:	$4.78M
Gross Profit:	$896 000 (18.76 %)
EPS:	$-0.240

Q2	2023
Revenue:	$4.77M
Gross Profit:	$1.14M (23.82 %)
EPS:	$0.0995

Financial Reports:

No articles found.

Mediwound Ltd

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.